We provide you with 20 years of free, institutional-grade data for DRMA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of DRMA. Explore the full financial landscape of DRMA stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about DRMA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Dermata Therapeutics, Inc.(NASDAQ:DRMA) 
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clin...
Website: https://www.dermatarx.com
Founded: 2014
IPO Price: $7 (Aug 13, 2021)
Full Time Employees: 8
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends